pravastatin and serine
pravastatin has been researched along with serine in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Crisby, M; Högberg, J; Pääjärvi, G; Roudier, E; Stenius, U | 1 |
| Gao, L; Ge, JB; Xu, B; Yao, K | 1 |
Other Studies
2 other study(ies) available for pravastatin and serine
| Article | Year |
|---|---|
HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage.
Topics: Animals; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Enzyme Inhibitors; Female; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Insulin; Liver; Liver Neoplasms; Nuclear Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pravastatin; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serine; Sirolimus; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2005 |
Pravastatin activates platelet nitric oxide synthase (NOS) in patients with type 2 diabetes mellitus and NOS activation is accompanied by serine phosphorylation.
Topics: Blood Platelets; Diabetes Mellitus, Type 2; Enzyme Activation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Phosphorylation; Pravastatin; Serine | 2005 |